國立虎尾科技大學 |

PARP Inhibitors for Cancer Therapy

Record Type:	Language materials, printed : Monograph/item
Title/Author:	PARP Inhibitors for Cancer Therapy/ edited by Nicola J. Curtin, Ricky A. Sharma.
other author:	Curtin, Nicola J.
Description:	XIX, 591 p. 108 illus., 85 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Cancer research. -
Online resource:	https://doi.org/10.1007/978-3-319-14151-0
ISBN:	9783319141510

PARP Inhibitors for Cancer Therapy
PARP Inhibitors for Cancer Therapy[electronic resource] /edited by Nicola J. Curtin, Ricky A. Sharma. - 1st ed. 2015. - XIX, 591 p. 108 illus., 85 illus. in color.online resource. - Cancer Drug Discovery and Development,2196-9906. - Cancer Drug Discovery and Development,.

History of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.

PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP—poly ADP ribose polymerase—in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors—PARPi—are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The “synthetic lethality” of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.

ISBN: 9783319141510

Standard No.: 10.1007/978-3-319-14151-0doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

PARP Inhibitors for Cancer Therapy
LDR:03912nam a22004095i 4500 001 963363
003 DE-He213
005 20200707031021.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319141510 $9 978-3-319-14151-0
024 7 $a 10.1007/978-3-319-14151-0 $2 doi
035 $a 978-3-319-14151-0
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a PARP Inhibitors for Cancer Therapy $h [electronic resource] / $c edited by Nicola J. Curtin, Ricky A. Sharma.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2015.
300 $a XIX, 591 p. 108 illus., 85 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Drug Discovery and Development, $x 2196-9906
505 0 $a History of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.
520 $a PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP—poly ADP ribose polymerase—in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors—PARPi—are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The “synthetic lethality” of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.
650 0 $a Cancer research. $3 1253664
650 0 $a Drug resistance. $3 872072
650 0 $a Molecular biology. $3 583443
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Drug Resistance. $3 782695
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Curtin, Nicola J. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1258331
700 1 $a Sharma, Ricky A. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1258332
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319141503
776 0 8 $i Printed edition: $z 9783319141527
776 0 8 $i Printed edition: $z 9783319344898
830 0 $a Cancer Drug Discovery and Development, $x 2196-9906 $3 1253870
856 4 0 $u https://doi.org/10.1007/978-3-319-14151-0
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)